For the past several years, the halls of the Las Vegas Convention Center have been lousy with AR/VR/XR smart glasses. While ...
A specialty pharmacy company agreed to a $1.67 million settlement that it gave inventory management systems to retina ...
SolidddVision smartglasses, which correct vision for people living with vision loss due to macular degeneration, will debut at CES.
Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...
The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.
The Brighterside of News on MSN3d
New eye drops successfully treat age-related macular degenerationToll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...
Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in ...
Astellas Pharma Inc. (ALPMY, ALPMY) announced that the U.S. Food and Drug Administration accepted the revised supplemental New Drug ...
SolidddVision smart glasses aim to restore vision for people living with macular degeneration, a condition that affects ...
LAS VEGAS and NEW YORK, Jan. 6, 2025 /PRNewswire/ -- SolidddVision™ smartglasses, the first true vision correction for people ...
Seeking Alpha on MSN1d
EyePoint initiated at buy by Citi on wAMD drug potentialCiti has initiated coverage of EyePoint (EYPT) with a buy rating, stating it sees the company's drug Duravyu as well-positioned to compete in the wAMD market. Read more here.
Lenvatinib is under clinical development by AiViva BioPharma and currently in Phase II for Diabetic Macular Edema.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback